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Patient and hospital characteristics predictive
of inferior vena cava filter usage in venous
thromboembolism patients
A study from the 2013 to 2014 Nationwide Readmissions
Database
Amie Goodin, PhD, MPPa,
∗
, Ming Chen, MSa, Driss Raissi, MDb, Qiong Han, MD, PhDb,
Hong Xiao, PhDa, Joshua Brown, PharmD, PhDa
Abstract
To examine the association between patient and hospital characteristics and inferior vena cava filter (IVCF) utilization in patients with
venous thromboembolism (VTE).
The 2013 to 2014 Nationwide Readmissions Database was used to define a cohort of patients with VTE aged ≥18 after a primary
VTE diagnosis. Comorbidities of interest were classified via diagnosis codes and IVCF placement was identified via procedure code.
Chi square analysis tested differences between patient and hospital-level characteristics and whether or not IVCFs were placed. A
hierarchical logistic regressionmodel estimated the relationship between patient-level factors (demographics, socioeconomic status,
comorbidities), hospital-level factors (bed size, teaching status, urbanity) and whether or not IVCFs were placed. Additional models
were specified to examine goodness of fit across methodological alternatives.
There were 212,395 VTE hospitalizations, with 12.18% (n=25,877) receiving IVCF placement. There were significant differences
between those who did and did not receive IVCF placement; notably, those receiving IVCFs were older (P< .001), had Medicare
insurance more than private (P< .001), longer lengths of stay (P< .001), and were in privately owned hospitals (P< .001). IVCF
placement remained significantly associated with patient and hospital-level characteristics following multivariate adjustment via
hierarchical logistic regression; notably, age >80 (adjusted Odds Ratio [aOR]: 2.53, 95% confidence interval [CI]: 2.25–2.85), ≥13
comorbid conditions (aOR: 3.85, 95% CI: 3.25–4.27), and privately owned hospitals (aOR: 1.21, 95% CI: 1.08–1.36). Optimal
goodness-of-fit was achieved with a combination of random effects and patient-level fixed effects.
These findings provide evidence that combinations of patient and hospital-level factors are related to whether patients with VTE
receive IVCFs.
Abbreviations: ACCP = American College of Chest Physicians, AHRQ = Agency for Healthcare Research and Quality, AIC =
Akaike information criterion, BIC = Bayesian information criterion, CI = confidence interval, DVT = deep vein thrombosis, ICC =
intraclass correlation coefficient, ICD = International Classification of Disease, IVCF = inferior vena cava filter, NRD = Nationwide
Readmissions Database, PE = pulmonary embolism, SIR = Society for Interventional Radiology, VTE = venous thromboembolism.
Keywords: claims data, inferior vena cava filters, venous thromboembolism
1. Introduction
Inferior vena cava filters (IVCFs) may be used as secondary
prevention after venous thromboembolism (VTE), and are also
used prophylactically for the prevention of pulmonary embolism
(PE) in patients meeting certain high-risk criteria such as failed or
contraindicated anticoagulation.[1] Despite the increased risk for
VTE recurrence after IVCF placement,[2,3] device-related com-
plications,[4] and recommendation that indications for IVCFs be
“rare” in patients with deep vein thrombosis (DVT) and PE,[5]
IVCFs continue to be employed prophylactically and therapeuti-
cally in patients with VTE.
In 2005, the PREPIC study conducted a randomized controlled
trial of permanent IVCF placements in patients with DVT and
followed up for 8 years; it was reported that IVCFs reduced PE
risk but increased DVT, with overall no effect on survival rates.[3]
A 2015 randomized controlled trial (the PREPIC2 study) of
retrievable IVCFs reached similar conclusions: where patients
with VTE were given either retrievable IVCFs and anticoagu-
lation or anticoagulation alone there were no discernible
differences in recurrent PE after 3 months.[6] Evidence on IVCF
effectiveness from studies in particular subgroups remains mixed.
One observational study in 2012 reported that in-hospital
mortality rates were lower in stable patients who received IVCFs
as well as in unstable patients receiving thrombolytic therapy.[7]
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A 2014 observational study also reported a decrease in in-
hospital mortality in unstable adults with PE that received
IVCFs.[8]
Recent studies of IVCF usage in cancer patients with VTE have
demonstrated clinically poor outcomes. One 2017 population-
based study of hospital discharge records found a higher 180-day
risk of recurrent DVT in patients with cancer who received
IVCFs, whereas these patients received no reduction of either
180-day PE risk or 30-day mortality.[9] Another 2017 retrospec-
tive cohort analysis of cancer and noncancer Canadian patients
found that 21% of IVCF placements occurred in patients with no
anticoagulation contraindication and that a greater proportion of
these patients (31%) had active cancer(s) and a high short-term
mortality rate, which suggests possible inappropriate IVCF
placement in end-of-life care settings in this population.[10] In
addition, a 2017 meta-analysis of IVCF placements from
randomized controlled trials in cancer and noncancer PE patients
concluded that there is no evidence for routine IVCF use in these
populations as evidenced by a lack of reduction in both absolute
and relative risk after IVCF placement.[11]
Emerging evidence in the literature suggests that patients with
VTE with either DVT or PE are more likely to receive an IVCF
placement if they have certain types of cancers, if they have
characteristics deemed high risk for bleeding from anticoagula-
tion therapies, or if they are treated in hospitals that have certain
characteristics.[12] The purpose of this study is to expand on
previous work to examine the association between patient and
hospital characteristics and IVCF utilization in patients with VTE
using a large sample retrospective cohort design.
2. Materials and methods
The Agency for Healthcare Research and Quality (AHRQ) 2013
and 2014 Nationwide Readmissions Database (NRD) were used
in this retrospective cohort study. The NRD database includes
all-payer administrative hospital discharge claims from 21 states
in 2013 and 22 states in 2014 with unique patient identifiers to
facilitate follow-upwithin each calendar year, which accounts for
85% of the discharges from all the State Inpatient Database. In
addition to patient demographic information (eg, age, sex, race,
and zip-code income), and diagnostic and procedural informa-
tion from the NRD Core File, information on severity of illness
and comorbidities were also identified by linkages via patient
identification number in the NRD Severity File. Hospital
characteristics (eg, bed size, ownership, teaching status, rural,
or urban) were included from the NRD Hospital File and linked
via hospital identifiers to patient data within each calendar year.
NRD data are deidentified and publicly available; hence, this
study was deemed exempt from institutional review board
review.
2.1. Study population: cohort definition
The study cohort was defined as all VTE cases in patients aged 18
years and older, based on International Classification of Disease
Codes version 9 (ICD-9), with primary diagnoses of either DVT
(ICD-9 Codes 451.xx and 453.xx) or PE (ICD-9 Codes 415.1x).
Index hospitalization for patients with VTE was identified as the
first hospitalization within each calendar year. Elective index
hospitalizations were excluded. IVCF placements were identified
by ICD-9 procedural code 38.7 at any point in the 2013 to 2014
data following initial PE or DVT diagnosis. Hospitals that did not
have the capacity to conduct IVCF placement, defined as
performing zero IVCF procedures within the study period, were
excluded to avoid bias of hospital-level characteristics. Hospitals
were also required to have aminimum of 55 VTE hospitalizations
during the study period to calculate reliable point estimates and
95% confidence intervals (CIs).
2.2. Variable definitions
Patients with VTE were categorized as DVT or PE according to
blood clot location. Patients with DVT were further classified by
location of DVT to lower (ICD-9Codes 451.0x, 451.1x, 451.2x,
451.81, 453.4, 453.5, 453.6), deep (ICD-9 Codes 451.1x,
cc451.81, 453.4, 453.5, 453.72, 453.82), proximal (ICD-9
Codes 451.81, 453.41, 453.51), andmigrant DVT (ICD-9Codes
453.1). Patient demographic, admission-related, and socioeco-
nomic variables were also included. Age was categorized by 10-
year intervals, (eg, 18–29, 30–39, 39–40, etc). Admission day
was categorized as on the weekend or on a weekday. Patient
health insurance was classified as Medicare, Medicaid, private
insurance, self-pay, no charge, or other type of health insurance.
Median household income was reported as a quartile classifica-
tion of the patient’s zip code of residence. Patient location was
classified into 3 levels: the large metropolitan areas, small
metropolitan areas, and the micropolitan with other areas (rural).
Count of chronic conditions were aggregated into the following
categories: 0 conditions, 1 to 3 conditions, 4 to 6, 7 to 9, 10 to 12,
and ≥13.
Comorbidity measures included 28 AHRQs comorbidities and
other comorbidities of interest. AHRQ comorbidities and other
comorbidities of interest were identified from the NRD severity
data file, and were selected based on previously published coding
algorithms.[13] Comorbidities of interest included hyperlipid-
emia, chronic obstructive pulmonary disorder, stroke, sepsis,
infection, trauma, bleeding, thrombolysis, embolectomy, and the
“unstable,” which refers to patients with shock or ventilator use.
Hospital characteristics included hospital ownership (eg,
Government, non-Federal; privately owned non-profit; private,
investment-owned), bed size, teaching status, and urban-rural
designation. Bed size classifications of “Small” “Medium,” and
“Large,” are operationalized by NRD according to a combina-
tion of hospital location and teaching status (ie, a “Small” bed
size in a rural northeast United States area may have 49 beds, but
49 beds is classified as “Medium” bed size in the rural
Midwestern United States).[14] Urban and rural classification
were based on population thresholds of residents in the hospital
county, where categories were grouped into large metropolitan
areas (≥1 million residents), small metropolitan areas (metropol-
itan area with <1 million residents), and micropolitan and other
rural areas.
2.3. Statistical analysis
Bivariate analysis via chi square analysis was performed to
compare patient and hospital characteristics between IVCF users
and nonusers after DVT or PE diagnosis at hospitalization.
Bivariate testing for any patient characteristic or condition with
<30 patients was conducted via Fisher exact test. A hierarchical
logistic regression model was constructed to analyze variance in
the binary outcome IVCF use, due to patient demographic and
clinical characteristics and hospital characteristics being at
hierarchical levels. Adjusted odds ratios and 95% CIs were
calculated after controlling for these factors, with a priori
significance set at 0.05.
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Four hierarchical models with hospital as random effects and
potential risk factors at the patient level and/or at the hospital
level as fixed effects were specified to test assumptions of the
original model and to explore goodness of fit across methodo-
logical alternatives. The intraclass correlation coefficient (ICC)
was calculated to quantify the variance of IVCF use between
hospitals and within hospitals. To account for variation of IVCF
use by hospitals, a random effects only model was built as Model
1. Model 2 only included level-1 (patient level) fixed effects, that
is, the patient characteristics potentially associated with IVCF use
as fixed effects. Model 3 was restricted to level-2 (hospital-level)
fixed effects. A full model including both level-1 and level-2 was
subsequently performed as model 4. C-statistics were used as a
measure of discrimination ability between IVCF use and no IVCF
use. Akaike information criterion (AIC) and Bayesian informa-
tion criterion (BIC) were calculated to assess the model fit across
the 5 specified hierarchical models. All analysis was conducted
using SAS version 9.4 (SAS Institute, Cary, NC).
3. Results
There were 212,395 patients with VTE in the NRDdatabase with
a primary diagnosis of either DVT (n=89,482) or PE (n=
122,913). Approximately 12.18% (n=25,877) of these under-
went IVCF placement during the study period and n=186,518
did not receive an IVCF. There were 1524 hospitals that
performed at least 55 IVCF procedures, with a range of 0.60% of
patients with VTE receiving IVCF to 47.10% of patients with
VTE receiving IVCF in these hospitals. Table 1 provides a
summary of patient and hospital characteristics, by patients who
Table 1
Patient and hospital characteristics by inferior vena cava filter use in all deep vein thrombosis and pulmonary embolism patients, from the
2013 to 2014 Nationwide Readmissions Database.
Characteristics
VTE patients receiving
VCFs (N=25,877)
VTE patients who did not
receive VCFs (N=186,518)
% Receiving
VCF
Patient characteristics (level 1) n (%) n (%) P %
Age
18–29 444 (1.72) 7876 (4.22) <.0001 5.34
30–39 848 (3.28) 13,200 (7.08) 6.04
40–49 2061 (7.96) 22,784 (12.22) 8.30
50–59 3770 (14.57) 32,800 (17.59) 10.31
60–69 5432 (20.99) 37,907 (20.32) 12.53
70–79 5832 (22.54) 36,582 (19.61) 13.75
80+ 7490 (28.94) 35,369 (18.96) 17.48
Sex
Male 12,282 (47.46) 89,095 (47.77) .3581 12.12
Female 13,595 (52.54) 97,423 (52.23) 12.25
Admission day
Workdays 20,445 (79.01) 145,720 (78.13) .0013 12.30
Weekends 5432 (20.99) 40,798 (21.87) 11.75
Insurance
Medicare 16,515 (63.82) 98,027 (52.56) <.0001 14.42
Medicaid 1982 (7.66) 20,119 (10.79) 8.97
Private insurance 5788 (22.37) 51,888 (27.82) 10.04
Self-pay 729 (2.82) 8614 (4.62) 7.80
No charge 136 (0.53) 1515 (0.81) 8.24
Other 727 (2.81) 6355 (3.41) 10.27
Median household income
0–25th percentile 7022 (27.14) 50,616 (27.14) .0688 12.18
26th–50th percentile 6651 (25.70) 48,547 (26.03) 12.05
51st–75th percentile 6106 (23.60) 44,707 (23.97) 12.02
76th–100th percentile 6098 (23.57) 42,648 (22.87) 12.51
Patient location (urban/rural status)
Large metropolitan 15,581 (60.21) 109,404 (58.66) <.0001 12.47
Small metropolitan 7684 (29.69) 59,097 (31.68) 11.51
Micropolitan/others 2612 (10.09) 18,017 (9.66) 12.66
Number of chronic conditions
0 353 (1.36) 7049 (3.78) <.0001 4.77
1–3 5282 (20.41) 56,207 (30.13) 8.59
4–6 9888 (38.21) 68,439 (36.69) 12.62
7–9 6956 (26.88) 38,188 (20.47) 15.41
10–12 2672 (10.33) 13,161 (7.06) 16.88
13+ 726 (2.81) 3474 (1.86) 17.29
DVT type
Lower DVT 21,052 (81.35) 97,409 (52.22) <.0001 17.77
Deep DVT 20,850 (80.57) 98241 (52.67) <.0001 17.51
Proximal DVT 13,286 (51.34) 55,161 (29.57) <.0001 19.41
Migrans DVT 32 (0.12) 90 (0.05) <.0001 26.23
(continued )
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Table 1
(continued).
Characteristics
VTE patients receiving
VCFs (N=25,877)
VTE patients who did not
receive VCFs (N=186,518)
% Receiving
VCF
Patient characteristics (level 1) n (%) n (%) P %
AHRQ comorbidity
Acquired immune deficiency syndrome 67 (0.26) 546 (0.29) .342 10.93
Alcohol abuse 963 (3.72) 5899 (3.16) <.0001 14.03
Deficiency anemia 7283 (28.14) 38,158 (20.46) <.0001 16.03
Rheumatoid arthritis/collagen vascular diseases 971 (3.75) 7013 (3.76) .952 12.16
Chronic blood loss anemia 756 (2.92) 1557 (0.83) <.0001 32.68
Congestive heart failure 2466 (9.53) 21,307 (11.42) <.0001 10.37
Chronic pulmonary disease 5600 (21.64) 40,308 (21.61) .9123 12.20
Coagulopathy 3134 (12.11) 12,226 (6.55) <.0001 20.40
Depression 2848 (11.01) 21,515 (11.54) .0123 11.69
Diabetes, uncomplicated 5501 (21.26) 35,799 (19.19) <.0001 13.32
Diabetes with chronic complications 922 (3.56) 7078 (3.79) .0665 11.53
Drug abuse 475 (1.84) 6078 (3.26) <.0001 7.25
Hypertension, uncomplicated and complicated 16,224 (62.7) 109,133 (58.51) <.0001 12.94
Hypothyroidism 3514 (13.58) 23,114 (12.39) <.0001 13.20
Liver disease 850 (3.28) 4802 (2.57) <.0001 15.04
Lymphoma 477 (1.84) 2833 (1.52) <.0001 14.41
Fluid and electrolyte disorders 7576 (29.28) 37,457 (20.08) <.0001 16.82
Metastatic cancer 3006 (11.62) 12,482 (6.69) <.0001 19.41
Other neurological disorders 3062 (11.83) 15,210 (8.15) <.0001 16.76
Obesity 4591 (17.74) 36,827 (19.74) <.0001 11.08
Paralysis 1042 (4.03) 3993 (2.14) <.0001 20.70
Peripheral vascular disorders 2013 (7.78) 7246 (3.88) <.0001 21.74
Psychoses 1056 (4.08) 8595 (4.61) .0001 10.94
Pulmonary circulation disorders 2429 (9.39) 25,516 (13.68) <.0001 8.69
Renal failure 3795 (14.67) 24,326 (13.04) <.0001 13.50
Solid tumor without metastasis 2171 (8.39) 9720 (5.21) <.0001 18.26
Peptic ulcer disease excluding bleeding 15 (0.06) 45 (0.02) .0030 25.00
Valvular disease 1139 (4.4) 9835 (5.27) <.0001 10.38
Weight loss 2110 (8.15) 8138 (4.36) <.0001 20.59
Other comorbidities
Hyperlipidemia 9115 (35.22) 63,043 (33.8) <.0001 12.63
COPD 7425 (28.69) 48,292 (25.89) <.0001 13.33
Stroke 1485 (5.74) 6189 (3.32) <.0001 19.35
Sepsis 666 (2.57) 1835 (0.98) <.0001 26.63
Infection/pneumonia 5201 (20.1) 28,650 (15.36) <.0001 15.36
Trauma 852 (3.29) 2924 (1.57) <.0001 22.56
Bleeding 2020 (7.81) 3432 (1.84) <.0001 37.05
Thrombolysis 2456 (9.49) 4793 (2.57) <.0001 33.88
Embolectomy 332 (1.28) 321 (0.17) <.0001 50.84
Unstable 1054 (4.07) 2388 (1.28) <.0001 30.62
Hospital characteristics (level 2)
Bed size
Small 1807 (6.98) 15,613 (8.37) <.0001 10.37
Medium 6765 (26.14) 50,992 (27.34) 11.71
Large 17,305 (66.87) 119,913 (64.29) 12.61
Ownership
Government, nonfederal 2851 (11.02) 21,291 (11.41) <.0001 11.81
Private, notprofit 18,483 (71.43) 135,931 (72.88) 11.97
Private, invest-own 4543 (17.56) 29,296 (15.71) 13.43
Urban-rural designation
Large metropolitan areas 16,277 (62.9) 112,746 (60.45) <.0001 12.62
Small metropolitan areas 8835 (34.14) 66,493 (35.65) 11.73
Nonmetropolitan areas 765 (2.96) 7279 (3.9) 9.51
Teaching status
Nonteaching 11,134 (43.03) 78,359 (42.01) .0019 12.44
Teaching 14,743 (56.97) 108,159 (57.99) 12.00
AHRQ = Agency for Healthcare Research and Quality, COPD = chronic obstructive pulmonary disorder, DVT = deep vein thrombosis, VCF = inferior vena cava filter, VTE = venous thromboembolism.
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underwent the IVCF procedure and patients who did not. In
bivariate analysis, patients who received IVCF were older
(P< .001), were admitted on a weekday more frequently than
on the weekend (P= .013), hadMedicare more often than private
insurance (63.82% IVCF Medicare vs 52.56% no IVCF
Medicare; P< .001), and had a greater number of chronic
conditions (P< .001). Patients with DVT and PE receiving IVCF
also were more likely to be treated in large metropolitan hospitals
(P< .001), nonteaching hospitals (P< .001), and private, invest-
ment-owned hospitals (P< .001), than patients who did not
receive IVCF.
Table 2 details results from the hierarchical logistic regression
results estimating the relationship between patient and hospital
characteristics associated with IVCF utilization. Following
multivariate adjustment, several patient and hospital-level
characteristics that were associated with IVCF placement
remained statistically significant. Patients with DVT and PE
with private insurance were 1.07 times more likely to receive
Table 2
Theassociationbetweeninferiorvenacavafilterutilizationandpatient
and hospital characteristics in patients with deep vein thrombosis or
pulmonary embolism, hierarchical logistic regression (n=212,395).
Characteristics
Adjusted
odds ratio 95% CI
Patient characteristics (level 1)
Age
18–29 Ref. Ref.
30–39 1.06 0.93–1.20
40–49 1.3 1.16–1.46
50–59 1.49 1.34–1.67
60–69 1.75 1.56–1.95
70–79 1.91 1.70–2.15
80+ 2.53 2.25–2.85
Sex
Male Ref. Ref.
Female 1 0.97–1.03
Admission day
Workdays Ref. Ref.
Weekends 0.99 0.96–1.03
Insurance
Medicare Ref. Ref.
Medicaid 0.93 0.88–0.99
Private insurance 1.07 1.02–1.12
Self-pay 0.89 0.81–0.98
No charge 0.9 0.74–1.10
Other 1.02 0.93–1.11
Median household income
0–25th percentile Ref. Ref.
26th–50th percentile 1 0.96–1.05
51st–75th percentile 1.06 1.02–1.11
76th–100th percentile 1.06 1.00–1.11
Patient location (urban/rural status)
Micropolitan/other rural Ref. Ref.
Small metropolitan 0.81 0.76–0.87
Large metropolitan 0.76 0.70–0.82
Number of chronic conditions
0 Ref. Ref.
1–3 1.57 1.40–1.77
4–6 2.21 1.96–2.49
7–9 2.79 2.45–3.17
10–12 3.34 2.90–3.85
13+ 3.85 3.25–4.57
DVT Type
Lower DVT 3.32 3.04–3.63
Deep DVT 1.16 1.06–1.26
Proximal DVT 1.22 1.18–1.26
Migrans DVT 1.63 1.02–2.59
AHRQ comorbidity
Acquired immune deficiency syndrome 0.87 0.66–1.14
Alcohol abuse 1.18 1.09–1.28
Deficiency anemias 1.15 1.11–1.19
Rheumatoid arthritis/collagen vascular diseases 0.89 0.82–0.96
Chronic blood loss anemia 2.59 2.33–2.88
Congestive heart failure 0.68 0.64–0.71
Chronic pulmonary disease 0.21 0.19–0.22
Coagulopathy 1.33 1.26–1.39
Depression 0.87 0.83–0.91
Diabetes, uncomplicated 0.95 0.92–0.99
Diabetes with chronic complications 0.73 0.67–0.79
Drug abuse 0.72 0.65–0.80
Hypertension, uncomplicated and complicated 0.88 0.85–0.91
Hypothyroidism 0.92 0.88–0.96
Liver disease 1.08 0.99–1.17
Lymphoma 1.03 0.93–1.15
(continued )
Table 2
(continued).
Characteristics
Adjusted
odds ratio 95% CI
Fluid and electrolyte disorders 1.24 1.20–1.28
Metastatic cancer 1.63 1.55–1.72
Other neurological disorders 1.18 1.13–1.24
Obesity 1.01 0.97–1.06
Paralysis 1.35 1.24–1.48
Peripheral vascular disorders 1.91 1.80–2.04
Psychoses 0.9 0.84–0.97
Pulmonary circulation disorders 0.28 0.26–0.30
Renal failure 0.76 0.73–0.80
Solid tumor without metastasis 1.66 1.57–1.75
Peptic ulcer disease excluding bleeding 0.61 0.32–1.16
Valvular disease 0.72 0.67–0.77
Weight loss 1.19 1.12–1.26
Other comorbidities
Hyperlipidemia 0.87 0.84–0.90
COPD 5.1 4.69–5.55
Stroke 1.17 1.09–1.27
Sepsis 1.24 1.11–1.40
Infection/pneumonia 1.19 1.14–1.24
Trauma 2.03 1.86–2.22
Bleeding 3.53 3.30–3.77
Thrombolysis 3.15 2.97–3.34
Embolectomy 4.45 3.72–5.33
Unstable 1.96 1.78–2.15
Hospital characteristics (level 2)
Bed size
Small Ref. Ref.
Medium 1.1 0.99–1.22
Large 1.22 1.10–1.35
Hospital ownership
Government, nonfederal Ref. Ref.
Private, notprofit 0.96 0.87–1.06
Private, invest-own 1.21 1.08–1.36
Urban-rural designation
Nonmetropolitan areas Ref. Ref.
Small metropolitan areas 1.48 1.26–1.72
Large metropolitan areas 1.69 1.44–1.99
Teaching status
Nonteaching Ref. Ref.
Teaching 0.98 0.91–1.04
AHRQ = Agency for Healthcare Research and Quality, CI = confidence interval, COPD = chronic
obstructive pulmonary disorder, DVT = deep vein thrombosis.
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IVCFs when compared with patients with Medicare (95% CI:
1.02–1.12), whereas patients with Medicaid insurance were 7%
less likely to receive IVCFs when compared with patients with
Medicare (95% CI: 0.88–0.99). Older patients, specifically those
older than 80 years, were 2.53 times more likely to receive IVCFs
than younger patients aged 18 to 29 years (95% CI: 2.25–2.85).
Patients who had many chronic conditions were also more likely
to receive IVCFs; those with 13 or greater conditions were 3.85
times more likely to receive IVCF (95%CI: 3.25–4.57) compared
to patients without chronic conditions. A solid tumor without
metastasis diagnosis resulted in 1.66 times greater likelihood of
receiving IVCF placement (95% CI: 1.57–1.75).
At the hospital level, teaching status was not a significant
predictor of whether or not a DVT or PE patient received IVCF.
Private, investment ownership of a hospital, however, was
associated with a 1.21 times greater likelihood of IVCF
placement (95% CI: 1.08–1.36). Large metropolitan hospitals
also placed IVCFs 1.69 times more often than micropolitan/rural
hospitals (95% CI: 1.44–1.99), as did small metropolitan
hospitals (adjusted Odds Ratio [aOR]: 1.48; 95% CI: 1.26–
1.72), and hospitals with large bed sizes (aOR: 1.22; 95% CI:
1.10–1.35).
Table 3 includes a comparison of the fit statistic results for 4
model fitting methodologies. Complete regression results for each
model fitting are available from the authors. Taken in
combination, AIC and BIC results (lower scores are better) also
suggest that the full Model 4, which included fixed effects for
hospital and patient characteristics and the random effects
intercept for between hospital variation, was optimal. Model 4
also fit the data well with a c-statistics of 0.80. In this final model,
the ICC showed that 7.51%of the model variation was explained
by the between hospital variation, that is, the random effects
intercept.
4. Discussion
A previous study employing this design was limited to discharge
data in a single state (Kentucky).[13] Overall, the findings using
this larger cohort and nationwide data suggest that patients with
DVT and PE who are treated at large, investment-owned private
hospitals may be more likely to receive an IVCF placement than
similar patients treated at smaller, nonprofit, and/or Government
hospitals. Patient characteristics such as having many comor-
bidities are also associated with whether or not they receive IVCF
placement and this supports findings from the Kentucky study.
This study did not include as many cancer-related comorbidities
as in previous work, however, which were found to be significant
patient-level factors related to IVCF utilization and so should be
explored in future analyses using the larger, nationwide cohort.
In addition, it should be noted that the overall hospital-level
factors, as gauged by hospital-level random effects, were found to
be a smaller contributor to variation in IVCF utilization when
compared with patient-level factors in this study. These findings
support evidence from the previous Kentucky study that reached
similar conclusions using a single-state analysis of hospital
variation in IVCF utilization, where residual variation between
hospital IVCF utilization rates was reported to be low after
controlling for patient case mix and hospital characteristics.[15]
The present study and the previous Kentucky study showed
smaller variation than a California-based study in which the
between-hospital variation was approximately 12% and the
range in IVCF use was more dispersed.[12] Although the NRD
data did not permit a state-based analysis, comparing the results
imply not only hospital level variation, but state-based variation
in IVCF use as well.
Although anticoagulation is the mainstay of VTE treatment,
IVCF placement is indicated for patients when anticoagulation is
contraindicated, for example, concurrent intracranial hemor-
rhage, massive gastrointestinal bleed, or imminent planned
surgery, or when patient has failed anticoagulation therapy, for
example, development of PE while on anticoagulation therapy.[1]
In other words, the decision for IVCF placement is largely
clinical, and the type of patient cohort at each institution or
practice is likely to dictate the percentage of patients with VTE
receiving IVCFs, leading to much variation in IVCF usage across
different institutions. Furthermore, the current guideline encour-
ages the usage of temporary instead of permanent IVCF and filter
retrieval as soon as clinically appropriate;[16] although, emerging
evidence suggests that the initiation of anticoagulation therapy is
only weakly associated with temporary IVCF retrieval, which
would indicate that there are other barriers to the timely retrieval
of IVCFs after placement.[17]
In the United States, there are 2 major guideline statements that
address IVCF implantation practices in patients with VTE: the
American College of Chest Physicians (ACCP) guidelines on the
management of VTE and the Society for Interventional
Radiology (SIR) guidelines for the management of PE. ACCP
guidelines do not call for prophylactic use and only recommend
Table 3
Comparison of fit statistics for hierarchical regression modeling in the association of inferior vena cava filter utilization and patient and
hospital characteristics.
Model 1 Model 2 Model 3 Model 4
Random
effects only
Model 1+ level 1
∗
fixed effects
Model 1+ level 2†
fixed effects
Model 1+ level 1 and
level 2 fixed effects
Intercept (SE) 2.10 (0.015) 5.47 (0.480) 1.82 (0.046) 5.72 (0.481)
Hospital random effects (SE) 0.28 (0.014) 0.28 (0.015) 0.26 (0.013) 0.27 (0.014)
ICC (%)‡ 7.82 7.93 7.41 7.51
C-statistic 0.66 0.80 0.65 0.80
AICx 154,280.70 132,038.50 154,210.00 131,962.70
BICx 154,291.50 132,406.80 154,258.80 132,369.00
AIC = Akaike information criterion, BIC = Bayesian information criterion, ICC = intraclass correlation coefficient, SE = standard error.
∗
Level 1: patient-level characteristics.
† Level 2: hospital-level characteristics.
‡ The ICC accounts for the variance of VCF use between hospitals and within hospitals.
x AIC and BIC assess the model fit by penalizing the addition of parameters (eg, smaller values indicate better fit).
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IVCF placement in cases of contraindication for anticoagula-
tion.[1] SIR guidelines, however, recommend prophylactic use in
patients with VTE at high risk for bleeding and/or are
contraindicated for anticoagulation therapy.[18] The inconsis-
tencies between these intersocietal guidelines, along with loose
adherence to these societal guidelines and the increase in
availability of retrievable IVCF, all have been blamed for
significant overuse in IVCF.[19] Although the aforementioned
factors may play a significant role in the variation of IVCF
placement across the United States, several other factors may
have been largely overlooked.[20] IVCF use varies from country to
country, among the states within the United States and even at the
county level despite adjusting for clinical and socioeconomic
status.[12,21,22] Given that the efficacy of IVCF filters and its
impact on patient’s outcome remain a highly debated topic[23]
our study was designed to shed some light on potential
underlying hospital- and patient population–related factors that
may be contributing to whether patients receive or not receive
IVCFs as suggested by several articles.[13,24]
In our study 12.18% of patients with DVT and PE received an
IVCF placement during the study period, which is on the higher
side of the IVCF placement rates reported on the literature. This is
a more frequent occurrence than the currently recommended
“rare” usage of IVCFs.[5] Our results are suggestive of the fact
that certain financial factors may have some level of influence on
the rates of IVCFs placed. Patients with VTE with private
insurance are more likely to receive IVCFs, and patients admitted
to investment-owned private hospitals are also more likely to have
an IVCF placed. These findings may also explain the fact that
Medicare (more generous reimbursement thanMedicaid) patients
also have a higher IVCF placement rate than their Medicaid
counterparts; however, this could be limited by selection bias given
the fact that theMedicarepopulation is generally olderwithoverall
higher comorbidities and increased rates of absolute or relative
contraindications for anticoagulation therapy, leading to more
IVCF candidates in this population.[25] For a similar reason, such
demographic factors, such as older age orMedicaid insurance, can
also decrease the IVCF retrieval rate.[26]
Beyond financial factors, expertise availably may also have an
impact on IVCF placement rates as suggested by the higher
placement rates in urban settings and during weekdays as
compared with weekends. Several nonteaching hospitals have
limited access to IVCF implanting specialists, and the same is true
for nonurban hospitals. Many of these patients end up
transferred to another facility for filter placement, or simply
await regular working hours during the weekdays. These practice
patterns could explain some of the dynamics of IVCF placement
across the country. Also, therapeutic IVCF placement is not
usually considered a weekend emergency and the implanting
physician may defer placement to the first weekday in many
clinical circumstances. As expected, the presence of more
comorbidities did show a statistically significant correlation
with increased IVCF placement rate; a “sicker cohort” would
likely have overall clustering of underling VTE risk factors such
as cancer and also higher likelihood of having anticoagulation
contraindications.
There are several limitations with the analysis and study
design. First, follow-up after the initial DVT or PE diagnosis was
limited to the 2013 to 2014 study period, which means that
patients with VTEmay have received an IVCF placement at some
point after the study period and these patients would not be
labeled in our analysis as receiving IVCF. Longitudinal tracking
was not available for individual patients across calendar years
due to a lack of patient identification linkage variable, so
individual patients can only be analyzed within a year. No
medication use data were available; hence, we could not compare
patients who are contraindicated to anticoagulation, or patients
with anticoagulation failure. In addition, patients who received a
DVT or PE diagnosis at an NRD participating hospital may have
received IVCF at a hospital that does not report readmission
statistics to NRD, which would render our estimates of IVCF
usage as conservative. There are also limitations with under-
reporting and misclassification inherent to the use of administra-
tive data and diagnosis/procedure codes, so it is possible that
IVCF usage is conservatively recorded in this data. Also,
information on race was not included in NRD so race cannot
be examined using this data. The retrospective cohort study
design allows for the construction of a highly powered statistical
analysis with large sample sizes, but does present limitations to
the generalizability of these results due to the possibility of
selection bias. Last, the data used from this study were entirely
collected in the United States, so generalization to IVCF usage in
other countries is limited.
5. Conclusion
This study was undertaken to assess whether a combination of
patient and hospital-level factors correlates with the rate of IVCF
placement in patients with VTE. The findings in this study
contribute to the growing body of evidence that IVCFs may be
inappropriately employed in certainpopulations and that hospitals
should evaluate their dissemination of the most recent clinical
guidelines for treatment of “high-risk”DVT and PE patients. This
study indicated the need for additional research to investigate
whether the utilization of IVCFs could be explained by hospital
variation and patient characteristics at a national level.
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